Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;40(7):607-614.
doi: 10.1007/s40264-017-0530-5.

The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis

Leàn Rolfes  1   2 , Florence van Hunsel  3   4 , Laura van der Linden  5 , Katja Taxis  4 , Eugène van Puijenbroek  3   4
Affiliations

The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis

Leàn Rolfes et al. Drug Saf. 2017 Jul.

Abstract

Introduction: Clinical information is needed to assess the causal relationship between a drug and an adverse drug reaction (ADR) in a reliable way. Little is known about the level of relevant clinical information about the ADRs reported by patients.

Objective: The aim was to determine to what extent patients report relevant clinical information about an ADR compared with their healthcare professional.

Methods: A retrospective analysis of all ADR reports on the same case, i.e., cases with a report from both the patient and the patient's healthcare professional, selected from the database of the Dutch Pharmacovigilance Center Lareb, was conducted. The extent to which relevant clinical information was reported was assessed by trained pharmacovigilance assessors, using a structured tool. The following four domains were assessed: ADR, chronology, suspected drug, and patient characteristics. For each domain, the proportion of reported information in relation to information deemed relevant was calculated. An average score of all relevant domains was determined and categorized as poorly (≤45%), moderately (from 46 to 74%) or well (≥75%) reported. Data were analyzed using a paired sample t test and Wilcoxon signed rank test.

Results: A total of 197 cases were included. In 107 cases (54.3%), patients and healthcare professionals reported a similar level of clinical information. Statistical analysis demonstrated no overall differences between the groups (p = 0.126).

Conclusions: In a unique study of cases of ADRs reported by patients and healthcare professionals, we found that patients report clinical information at a similar level as their healthcare professional. For an optimal pharmacovigilance, both healthcare professionals and patient should be encouraged to report.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Leàn Rolfes, Florence van Hunsel, Laura van der Linden, Katja Taxis and Eugène van Puijenbroek declare that they have no conflicts of interest that are directly relevant to the content of this study.

Funding/support

No sources of funding were used to assist in the preparation of this study.

Figures

Fig. 1
Fig. 1
Number of reports with similar and deviating scores, per domain for patients and healthcare professionals
See this image and copyright information in PMC

References

    1. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. 2002 [cited 2016 Dec 1]. http://apps.who.int/medicinedocs/en/d/Js4893e/.
    1. US Food and Drug Administration. FDA adverse events reporting system (FAERS). 2016. [cited 2016 Feb 25]. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveil....
    1. Ishiguro C, Hall M, Neyarapally GA, Dal PG. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Pharmacoepidemiol Drug Saf. 2012;21(10):1134–1136. doi: 10.1002/pds.3317. - DOI - PubMed
    1. van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients; an 11-country survey. Drug Saf. 2012;35(1):45–60. doi: 10.2165/11594320-000000000-00000. - DOI - PubMed
    1. The EU pharmacovigilance system. 2012 [cited 2016 Feb 17]. http://ec.europa.eu/health/human-use/pharmacovigilance/index_en.htm.

LinkOut - more resources